Dogwood Therapeutics, Inc (NASDAQ:DWTX) Short Interest Up 61.2% in December

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 81,743 shares, an increase of 61.2% from the December 15th total of 50,720 shares. Based on an average daily volume of 72,259 shares, the days-to-cover ratio is currently 1.1 days. Approximately 3.7% of the shares of the stock are sold short. Approximately 3.7% of the shares of the stock are sold short. Based on an average daily volume of 72,259 shares, the days-to-cover ratio is currently 1.1 days.

Wall Street Analyst Weigh In

A number of research firms have weighed in on DWTX. Wall Street Zen lowered Dogwood Therapeutics to a “strong sell” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Monday, December 22nd. Finally, HC Wainwright upped their price objective on shares of Dogwood Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, September 30th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Dogwood Therapeutics has an average rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Price Performance

Shares of DWTX opened at $2.78 on Friday. The firm has a 50-day simple moving average of $5.17 and a two-hundred day simple moving average of $5.25. Dogwood Therapeutics has a 1-year low of $1.87 and a 1-year high of $29.28. The stock has a market cap of $6.37 million, a PE ratio of -0.11 and a beta of 1.90.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its earnings results on Thursday, November 6th. The company reported ($8.20) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($6.97). As a group, sell-side analysts expect that Dogwood Therapeutics will post -6.43 earnings per share for the current fiscal year.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.